Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZSDT for Recurrent Refractory Mantle Cell Lymphoma After BTK Inhibitor Failure
NCT07264894Phase 4Not yet recruiting
- Sponsor
- Zhengzhou University
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- IgG Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of hlx01, selinexor, dexamethasone, thalidomide in mantle cell lymphoma (MCL), sponsored by Zhengzhou University. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
hlx01selinexordexamethasonethalidomide
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT07264894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07264894.